Sentences with phrase «specific immune responses to tumor»

Dr. Gnjatic's research focuses on human antigen - specific immune responses to tumor antigens, in an attempt to define new targets for the development of cancer immunotherapies, assess the efficacy of these immunotherapies, and learn why they may fail.

Not exact matches

He also studies the mechanisms of antigen presentation to T cells, the impact of immunoregulation on tumor antigen - specific responses, and characterization of the tumor - immune microenvironment.

However, despite this success, the use of immunotherapy remains limited by the scarcity of tumor - specific antigens — substances that can trigger an immune system response to a particular type of cancer.

Most importantly, many of the T cells were able to recognize the tumor cells directly, demonstrating that the vaccine had triggered a tumor - specific immune response that could target the patient's tumor.

«Our results clearly demonstrate a significant, although unexpected, role for specific gut bacteria in enhancing the immune system's response to melanoma and possibly many other tumor types,» said study director Thomas Gajewski, MD, PhD, professor of medicine and pathology at the University of Chicago.

A personal cancer treatment vaccine that targets distinctive «neoantigens» on tumor cells has been shown to stimulate a potent, safe, and highly specific immune anti-tumor response in melanoma patients, report scientists from Dana - Farber Cancer Institute and the Broad Institute of MIT and Harvard.

Using transplantable tumor models expressing antigen in an inducible manner or spontaneous tumor models expressing nominal antigens, we try to decipher whether the tumor is ignored or leads to deletion, anergy or class switch of the specific immune response or generate suppressor T cells.

Cancer vaccines are designed to stimulate an immune response against tumor - specific or tumor - associated antigens, encouraging the immune system to attack cancer cells bearing these antigens.

Through her CLIP Grant, she is analyzing patient samples to determine how Poly ICLC (a TLR agonist) affects the tumor environment and immune responses against specific mutations, to identify how Poly ICLC could complement existing immunotherapies.

Therapeutic vaccines are designed to elicit an immune response against tumor - specific or tumor - associated antigens, encouraging the immune system to attack cancer cells bearing these antigens.

Therapeutic cancer vaccines are designed to elicit an immune response against tumor - specific or tumor - associated antigens, encouraging the immune system to attack cancer cells bearing these antigens.

Cancer vaccines are designed to elicit an immune response against tumor - specific or tumor - associated antigens.

Over the past few years, they have extended their research to understand how products of cellular necrosis and the innate immune responses they induce affect the tumor microenvironment, with a specific focus on ovarian cancer.

There, they will be exposed to tumor antigens released from dying glioma cells through TK + valacyclovir - induced glioma cell death, and thus mediate a specific anti-malignant glioma immune response against remaining malignant glioma cells.

They do, however, play a key role in helping to boost the anti-tumor immune response by: (1) expanding the number and improving the function of existing CTLs that are specific to the same tumor antigen; and (2) providing help to other immune cells, including B lymphocytes that are precursors to antibodies and natural killer (NK) cells that are also important in the overall anti-tumor immune response.

We believe DCs are the most important immune cells to target because they initiate the specific immune response that generates CTLs to kill the tumor.